Collects health information from people with blood cell disorders called myeloproliferative neoplasms
Records clinical and molecular information from people with myeloproliferative neoplasms over time.
Key facts
- Who runs it
- University Health Network, Toronto
- Where
- Toronto, CanadaSee the site
- Trial code
- Registry title
- Myeloproliferative Neoplasms (MPNs) Patient Registry
- Status
- Recruiting
- People taking part
- 5,000 people, planned
- Started
- Apr 2015
- Expected to end
- 31 Oct 2027
- Type of study
- Observational
- Treatments tested
- Observational
- Record updated
- 27 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for people with one of several myeloproliferative neoplasms (MPNs), a group of blood cell cancers. Clinical and molecular information is collected over time from people who give consent.
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of one of these MPNs: atypical CML, chronic eosinophilic leukemia (not otherwise specified), chronic myelomonocytic leukemia, chronic neutrophilic leukemia, essential thrombocythemia, juvenile myelomonocytic leukemia, mastocytosis, unclassifiable MPN, unclassifiable MPN/MDS, primary myelofibrosis, post-ET myelofibrosis, post-PV myelofibrosis, or RARS-T.
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Diagnosis of one of the following myeloproliferative neoplasms (MPNs):
- Atypical CML (aCML)
- Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),
- Chronic myelomonocytic leukemia (CMML)
- Chronic neutrophilic leukemia (CNL),
- Essential thrombocythemia (ET),
- Juvenile myelomonocytic leukemia (JMML),
- Mastocytosis, MPN unclassifiable
- MPN/MDS unclassifiable,
- Primary myelofibrosis (PMF),
- Post-essential thrombocythemia myelofibrosis (post-ET MF),
- Post-polycythemia vera MF (post-PV MF)
- Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)
Who cannot take part
- None
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaContact: Vikas Gupta, MDTaking people
About the trial
What the trial wants to find out
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
The group in the trial
- Patients with a diagnosis of MPN
Patients with a myeloproliferative neoplasm (MPN) diagnosis: Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T
Treatment: Observational
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)
- Plain-language title
- Collects health information from people with blood cell disorders called myeloproliferative neoplasmsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 August 2024